Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2–) Advanced Breast Cancer: A Systematic Literature Review
Gebra Cuyún Carter, Maitreyee Mohanty, Keri Stenger, et al.
Cancer Management and Research (2021) Vol. Volume 13, pp. 6537-6566
Open Access | Times Cited: 25

Showing 25 citing articles:

Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
Hope S. Rugo, Adam Brufsky, Xianchen Liu, et al.
npj Breast Cancer (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 76
Do proton pump inhibitors affect the effectiveness of cyclin-dependent kinase 4/6 inhibitors in advanced HR positive, HER2 negative breast cancer? A meta-analysis
Francisco Cézar Aquino de Moraes, Caroline R. M. Pereira, Vitor Kendi Tsuchiya Sano, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 6
Risk of Recurrence in Patients With HER2+ Early-Stage Breast Cancer: Literature Analysis of Patient and Disease Characteristics
Joyce O’Shaughnessy, William J. Gradishar, Ruth O’Regan, et al.
Clinical Breast Cancer (2023) Vol. 23, Iss. 4, pp. 350-362
Closed Access | Times Cited: 16
An Update and Translational Perspective in Genetics and Genomics of Breast Cancer
Kovuri Umadevi, Lalagiri Gnana Priyanka, Ruchira Clementina, et al.
Current Breast Cancer Reports (2025) Vol. 17, Iss. 1
Closed Access
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2–Negative Metastatic Breast Cancer
Pier Paolo Maria Berton Giachetti, Stefania Morganti, Sara Gandini, et al.
JAMA Network Open (2025) Vol. 8, Iss. 2, pp. e2461067-e2461067
Open Access
Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial
Nadia Harbeck, Véronique Dièras, Karen A. Gelmon, et al.
ESMO Open (2025) Vol. 10, Iss. 4, pp. 104497-104497
Closed Access
Pretreatment neutrophil to lymphocyte ratio as prognostic factor in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors
Pauline Rottier, George Emile, Alison Johnson, et al.
Frontiers in Oncology (2023) Vol. 12
Open Access | Times Cited: 9
Identification of Patients with Early HR+ HER2− Breast Cancer at High Risk of Recurrence
Peter A. Fasching, Hans Kreipe, Lucia Del Mastro, et al.
Geburtshilfe und Frauenheilkunde (2024) Vol. 84, Iss. 02, pp. 164-184
Open Access | Times Cited: 3
Multicenter Randomized Open-Label Phase II Clinical Study Comparing Outcomes of NK105 and Paclitaxel in Advanced or Recurrent Breast Cancer
Yoshimasa Kosaka, Toshiaki Saeki, Toshimi Takano, et al.
International Journal of Nanomedicine (2022) Vol. Volume 17, pp. 4567-4578
Open Access | Times Cited: 12
Effect of Cyclin-Dependent Kinase 4/6 Inhibitors on Circulating Cells in Patients with Metastatic Breast Cancer
Soraia Lobo-Martins, Patrícia Corredeira, Ana Cavaco, et al.
Cells (2024) Vol. 13, Iss. 16, pp. 1391-1391
Open Access | Times Cited: 2
Prediction of clinicopathological features, multi-omics events and prognosis based on digital pathology and deep learning in HR+/HER2− breast cancer
Jia Hu, Hong Lv, Shen Zhao, et al.
Journal of Thoracic Disease (2023) Vol. 15, Iss. 5, pp. 2528-2543
Open Access | Times Cited: 6
Efficacy of Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
Zaheer Qureshi, Abdur Jamil, Eeshal Fatima, et al.
American Journal of Clinical Oncology (2024) Vol. 47, Iss. 11, pp. 526-534
Closed Access | Times Cited: 1
Early stage breast cancer follow-up in real-world clinical practice: the added value of cell free circulating tumor DNA
Eliana La Rocca, Maria Carmen De Santis, M. Silvestri, et al.
Journal of Cancer Research and Clinical Oncology (2022) Vol. 148, Iss. 6, pp. 1543-1550
Open Access | Times Cited: 6
A quantitative characterization of the spatial distribution of brain metastases from breast cancer and respective molecular subtypes
Saeedeh Mahmoodifar, Dhiraj J. Pangal, Tyler Cardinal, et al.
Journal of Neuro-Oncology (2022) Vol. 160, Iss. 1, pp. 241-251
Open Access | Times Cited: 5
Association of Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count With Clinical Outcomes in Advanced Breast Cancer in the MONARCH 2 Trial
Eriko Tokunaga, Yasuo Miyoshi, Koji Dozono, et al.
The Oncologist (2023) Vol. 29, Iss. 3, pp. e319-e329
Open Access | Times Cited: 2
Transmembrane 4 L Six Family Member 1 Suppresses Hormone Receptor-–Positive, HER2-Negative Breast Cancer Cell Proliferation
Jie Chen, Jin Zhu, Shuai‐Jun Xu, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 3
Efficacy and Safety of Abemaciclib in Combination With Endocrine Therapy for HR+/HER2− Advanced or Metastatic Breast Cancer
Zaheer Qureshi, Abdur Jamil, Eeshal Fatima, et al.
American Journal of Clinical Oncology (2024)
Closed Access
Identifizierung von Patientinnen mit HR+, HER2– Brustkrebs im Frühstadium mit hohem Rezidivrisiko
Peter A. Fasching, Hans Kreipe, Lucia Del Mastro, et al.
Senologie - Zeitschrift für Mammadiagnostik und -therapie (2024) Vol. 21, Iss. 04, pp. 289-312
Open Access
Clever-1 positive macrophages in breast cancer
Minna Mutka, Reetta Virtakoivu, Kristiina Joensuu, et al.
Breast Cancer Research and Treatment (2022) Vol. 195, Iss. 3, pp. 237-248
Open Access | Times Cited: 2
Quality of life and overall survival are primary priorities of patients with advanced breast cancer: results of sociological research
Alina A. Kolomejtseva, Svetlana E. Bokova
Journal of Modern Oncology (2022) Vol. 24, Iss. 1, pp. 115-118
Open Access | Times Cited: 1
The effect of CDK4/6 inhibitors on the overall survival in patients with advanced HR+/HER2- BC in the entire population and in special clinical subgroups of unfavorable prognosis: A review
Katerina S. Grechukhina, M. V. Kalugin, A.A. Prosvirnov Prosvirnov, et al.
Journal of Modern Oncology (2023) Vol. 25, Iss. 1, pp. 55-62
Open Access
Precise subtyping reveals immune heterogeneity for hormone receptor-positive breast cancer
Mengyan Zhang, Xingda Zhang, Te Ma, et al.
Computers in Biology and Medicine (2023) Vol. 163, pp. 107222-107222
Closed Access
Nomogram for predicting distant metastasis and prognosis in HR+/HER2- breast cancer patients without lymph node metastasis
Weifang Zhang, Bo Liu, Fangjian Shang, et al.
Research Square (Research Square) (2023)
Open Access
Pretreatment neutrophil to lymphocyte ratio as prognostic factor in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors
Pauline Rottier, Angélique DA SILVA, Alison Johnson, et al.
Research Square (Research Square) (2022)
Open Access
A Quantitative Characterization of the Spatial Distribution of Brain Metastases from Breast Cancer and Respective Molecular Subtypes
Saeedeh Mahmoodifar, Dhiraj J. Pangal, Tyler Cardinal, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Page 1

Scroll to top